Primary axillary hyperhidrosis therapeutics market for the seven major markets is expected to grow to $680.7m by 2023, at a compound annual growth rate (CAGR) of 3.3%
This expected growth is due to increasing awareness of primary axillary hyperhidrosis as a treatable medical condition across the major developed markets, thus resulting in an increased diagnosis rate, and therefore a larger treatment-receiving population.
United States has the most hyperhidrosis cases amongst the major developed countries covered in this report. The reported prevalence rate for hyperhidrosis in the US is approximately 4.8%. Of these sufferers, 65% have axillary hyperhidrosis. In 2013, the reported prevalence rate for primary axillary hyperhidrosis in Japan was 5.75%, meaning nearly 2.23 million people suffered from severe symptoms of primary axillary hyperhidrosis. In 2016 the reported prevalence rate for primary focal hyperhidrosis in Germany was 4.6%. The reported prevalence rate for hyperhidrosis in the UK in 2005 stood at 1.62%. There are more than 1.2 million hyperhidrosis prevalent cases in Spain.
Allergan's Botox is the only approved product to treat primary axillary hyperhidrosis. Botox's major competitors are other botulinum toxin products such as Dysport and Xeomin, which are currently used off-label to treat the condition. Botox's revenue in this indication is expected to decline over the period due to competition from existing off-label products, and an increasing preference for medical devices that can provide permanent treatment for the disease.
Primary Axillary Hyperhidrosis in the Major Developed Markets will Show a Slight Increase in Growth Rate During the Forecast Period
How will the approved, late-stage and other off-label products contribute to market growth?
What will be the effect of approved medical devices on available drug therapies?
Key Topics Covered:
1. Executive Summary
2. Disease Overview
3. Impact of Hyperhidrosis
4. Treatment Patterns and Management
5. Marketed Products and Competitive Assessment
Botox - Allergan (Approved)
6. Marketed Medical Devices and Competitive Assessment
miraDry - Miramar Labs
PrecisionTX - Cynosure
7. Unmet Needs and Gap Analysis
8. Pipeline Analysis
Pipeline by Stage of Development and Molecule Type
Pipeline by Route of Administration and Molecular Target
9. Pipeline Products
10. Market Size and Forecast (Global, US, Japan, UK, Germany, France, Spain and Italy)